OncoCyte Corp OCX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OCX is a good fit for your portfolio.
News
-
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
-
Oncocyte Reports First Quarter 2024 Financial Results
-
Oncocyte to Announce First Quarter 2024 Financial Results
-
PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace
-
Oncocyte Reports Full Year 2023 Financial Results
-
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
-
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
-
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
Trading Information
- Previous Close Price
- $2.65
- Day Range
- $2.71–2.95
- 52-Week Range
- $2.08–4.86
- Bid/Ask
- $2.63 / $2.75
- Market Cap
- $36.62 Mil
- Volume/Avg
- 40,524 / 60,984
Key Statistics
- Price/Earnings (Normalized)
- 2.83
- Price/Sales
- 15.77
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 46
- Website
- https://www.oncocyte.com
Valuation
|
Metric
|
OCX
|
|---|---|
Price/Earnings (Normalized) | 2.83 |
Price/Book Value | 1.89 |
Price/Sales | 15.77 |
Price/Cash Flow | — |
Price/Earnings
OCX
Financial Strength
|
Metric
|
OCX
|
|---|---|
Quick Ratio | 0.69 |
Current Ratio | 0.78 |
Interest Coverage | −699.75 |
Quick Ratio
OCX
Profitability
|
Metric
|
OCX
|
|---|---|
Return on Assets (Normalized) | −24.07% |
Return on Equity (Normalized) | −63.35% |
Return on Invested Capital (Normalized) | −57.21% |
Return on Assets
OCX
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Pdshkkrm | Vdfr | $216.5 Bil | |
DHR
| Danaher Corp | Dpxdgdwgk | Mpyhr | $189.6 Bil | |
IQV
| IQVIA Holdings Inc | Zbgptlkb | Ddkghqn | $41.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Mrqwwhjnkl | Jwmqpwn | $41.2 Bil | |
A
| Agilent Technologies Inc | Whmcjvqdj | Gfhn | $38.0 Bil | |
MTD
| Mettler-Toledo International Inc | Lkxqcjzrc | Drkywbw | $30.0 Bil | |
ICLR
| Icon PLC | Drhzxyffz | Sjkqsw | $25.6 Bil | |
WAT
| Waters Corp | Wdmpljdtrx | Htjgm | $19.4 Bil | |
ILMN
| Illumina Inc | Yphsztwg | Bbvsn | $16.6 Bil | |
LH
| Labcorp Holdings Inc | Cfdlvplyb | Lbwbbp | $16.2 Bil |